David Shaw’s Apellis Pharmaceuticals APLS Stock Holding History

David Shaw’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,000	Closed	-$377K	–	4516
2025 Q4	$377K	Hold	15,000	–	–	﹤0.01%	4057
2025 Q3	$339K	Sell	15,000 -7,700	-34%	-$180K	﹤0.01%	4049
2025 Q2	$393K	Sell	22,700 -15,400	-40%	-$285K	﹤0.01%	3743
2025 Q1	$833K	Buy	38,100 +7,100	+23%	+$196K	﹤0.01%	3201
2024 Q4	$989K	Buy	+31,000	New	+$932K	﹤0.01%	3208

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

David Shaw's APLS Position: Q2 2026 in Review

David Shaw sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 186,853 shares — an estimated $7.52M sold.

David Shaw first reported a position in APLS in Q3 2019 and held it in 23 quarters. The position peaked at $48.1M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

David Shaw reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
David Shaw sold 186,853 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.52M.
David Shaw first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 23 quarters.
David Shaw's Apellis Pharmaceuticals position peaked at $48.1M in Q2 2023.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.